Significance of microvessel density in prostate cancer core biopsy

Aleksandra Salapura Dugonjić; Slavica Knežević Ušaj; Živka Eri; Ljiljana Tadić Latinović

doi:10.2298/4865

Aleksandra Salapura Dugonjić Institute for Pathology, Clinical Center of Banja Luka, Republic of Srpska, Bosnia and Herzegovina
Slavica Knežević Ušaj Institute for Pathology, Institute for Pulmonary Diseases, Sremska Kamenica, Srbija
Živka Eri Institute for Pathology, Institute for Oncology, Sremska Kamenica, Srbija
Ljiljana Tadić Latinović Institute for Pathology, Clinical Center of Banja Luka, Republic of Srpska, Bosnia and Herzegovina

DOI: https://doi.org/10.2298/4865

Keywords: prostatic neoplasms, biopsy, fine-needle, prostatectomy, immunohistochemistry, neovascularization, pathologic,

Abstract

Background/Aim. In prostate tumors, angiogenesis, measured as microvessel density, is associated with tumor stage and Gleason score. The aim of this study was determine neovascularization of prostatic adenocarcinomas in core biopsies and corresponding prostatectomies. Methods. The study population included 61 patients who underwent radical prostatectomy (RP) for localized prostate carcinoma patients and did not receive chemohormonal, or radiation therapy before surgery. Tumor blocks were immunostained using the endothelial-specific antibody CD31 and subsequently evaluated at ´ 400 magnification in both biopsies and corresponding prostatectomies. Results. When comparing microvessel density in core biopsies and corresponding prostatectomies, no statistically significant difference was found (p > 0.1). A statistically significant positive correlation was found when determining correlation between microvessel density (as linear and categorical variable, i.e. with the cut-off value of 48) that was associated with the Gleason score (p < 0.05) and tumor stage (p < 0.0001). There was no correlation between microvessel density and preoperative values of serum prostate-specific antigen (PSA) (p > 0.1). Conclusion. Microvessel density can be reliably applied to needle prostate biopsy specimens. Quantification of the microvascular density in biopsies is an accurate pre-operative predictor of tumor stage, discriminating between organ-confined and organ-extending neoplasms.

Author Biography

Aleksandra Salapura Dugonjić, Institute for Pathology, Clinical Center of Banja Luka, Republic of Srpska, Bosnia and Herzegovina

Zavod za patologiju, Klinicki centar Banja Luka, Banja Luka, Bosna i Hercegovina

References

Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oes-terling JE, et al. Combination of prostate-specific antigen, clini-cal stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277(18): 1445−51.

Oesterling JE. Prostate specific antigen: a critical assesment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145(5): 907−32.

Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271(5): 368−74.

Di Lorenzo G, De Placido S, Autorino R, De Laurentiis M, Mignogna C, D'Armiento M,. Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease. Prostate Cancer Prostatic Dis 2005;8(1):54-59.

Gettman MT, Bergstralh EJ, Blute M, Zincke H, Bostwick DG. Pre-diction of patient outcome in pathologic stage T2 adenocarci-noma of the prostate: lack of significance for microvessel den-sity analysis. Urology 1998; 51(1): 79−85.

Mucci LA, Powolny A, Giovannucci E, Liao Z, Kenfield SA, Shen R, et al. Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol 2009; 27(33): 5627−33.

Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate specific antigen, clinical stage and Glea-son score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150(1): 110−4.

Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: re-sults at 10 years. J Urol 1994; 152(5 Pt 2): 1831−6.

Jiang J, Chen Y, Zhu Y, Yao X, Qi J. Contrast enhanced ultraso-nography for the detection and characterisation of prostate cancer: correlation with microvessel density and Gleason score. Clin Radiol 2011; 66(8): 732−7.

Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med 1998; 49: 407−24.

Nagy JA, Dvorak AM, Dvorak HF. Vascular hyperpermeability, angiogenesis, and stroma generation. Cold Spring Harb Pers-pect Med 2012; 2(2): a006544.

Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel matura-tion in human tumors: implications for anti-angiogenic tumor therapies. Cancer Res 2000; 60(5): 1388−93.

Weidner N. Current pathologic methods for measuring intra-tumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995; 36(2): 169−80.

Russo G, Mischi M, Scheepens W, De la Rosette JJ, Wijkstra H. An-giogenesis in prostate cancer: onset, progression and imaging. BJU Int 2012; 110(11 Pt C): E794−808.

Steiner I, Jung K, Miller K, Stephan C, Erbersdobler A. Expression of endothelial factors in prostate cancer: a possible role of caveolin-1 for tumour progression. Oncol Rep 2012; 27(2): 389−95.

Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991; 324(1): 1−8.

Weidner N, Folkmann J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, et al. Tumor angiogenesis: a new significant and independent prognostic factor in early-stage breast carcinoma. J Natl Cancer Inst 1992; 84(24): 1875−87.

Rogatsch H, Hittmair A, Reissigl A, Mikuz G, Feichtinger H. Mi-crovessel density in core biopsies of prostatic adenocarci-noma: a stage predictor?. J Pathol 1997; 182(2): 205−10.

Albertsen PC, Hanley JA, Barrows GH, Penson DF, Kowalczyk PD, Sanders MM, et al. Prostate cancer and the Will Rogers pheno-menon. J Natl Cancer Inst 2005; 97(17): 1248−53.

Epstein JI, Netto GJ. Prostate biopsy interpretation. 4th ed. Philadelphia, PA: Lippincott Williams Wilkins; 2008.

Bostwick DG, Wheeler TM, Blute M, Barrett DM, MacLennan GT, Sebo TJ, et al. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology 1996; 48(1): 47−57.

Kuniyasu H, Troncoso P, Johnston D, Bucana CD, Tahara E, Fidler IJ, et al. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ confined from pathologically advanced prostate cancers. Clin Cancer Res 2000; 6(6): 2295−308.

Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor vo-lume and benign hyperplasia. J Urol 1990; 143(4): 747−52.

Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA. Predic-tors of pathologic stage in prostatic carcinoma: the role of neovascularity. Cancer 1994; 73(3): 678−87.

Rubin MA, Buyyounouski M, Bagiella E, Sharir S, Neugut A, et al. Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage and clinical outcome. Urology 1999; 53(3): 542−47.

Daris B, Munda M, Hajdinjak T, Kavalar R, Štiblar-Martičić D. Comparison of microvessel density and PSA level in prostatic adenocarcinoma of Gleason score 6 and 7. Acta Medico Bio-tech 2012; 5(1): 54−60.

Bostwick DG, Meiers I. Neoplasms of the prostate. In: Bostwick DG, Cheng L, editors. Urologic surgical pathology. 2nd. Edin-burgh: Mosby Elsevier. 2008. p. 443−580.

Tomioka S, Nakatsu H, Suzuki N, Murakami S, Matsuzaki O, Shimazaki J. Comparison of Gleason grade and score between preoperative biopsy and prostatectomy specimens in prostate cancer. Int J Urol 2006; 13(5): 555−9.

King CR, McNeal JE, Gill H, Brooks JD, Srinivas S, Presti JC Jr. Reliability of small amounts of cancer in prostate biopsies to reveal pathologic grade. Urology 2006; 67(6): 1229−34.

Versalainen S, Lipponen P, Talja M, Alhava E, Syrjanen K. Tumor vascularity and basement membrane structure as prognostic factors in T1-2M0 prostatic adenocarcinoma. Anticancer Res 1994;14: 709−14.

Haese A, Vaisanen V, Lilja H, Kattan M, Rittenhouse H, Pettersson K, et al. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade. J Urol 2005; 173(3): 752−6.

Bluestein DL, Bostwick DG, Bergstralh EJ, Oesterling JE. Eliminat-ing the need for bilateral pelvic lymphadenectomy in select pa-tients with prostate cancer. J Urol 1994; 151(5): 1315−20.

Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267(16): 10931−4.

Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, et al. Angiogenesis and prostate cancer: In vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 1998; 51(1): 161−7.

Weidner N, Caroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate cancer. Am J Pathol 1993; 143(2): 401−9.

Offersen BV, Borre M, Overgaard J. Immunohisto-chemical de-termination of tumor angiogenesis measured by the maximal microvessel density in human prostate cancer. APMIS 1998; 106(4): 463−9.

Pallares J, Rojo F, Iriarte J, Morote J, Armadans LI, de Torres I. Study of microvessel density and the expression of the angi-ogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histol Histopathol 2006; 21(8): 857−65.

Borre M, Nerstrøm B, Overgaard J. Association between immuno-histochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tu-mor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res 2000; 6(8): 1882−90.

Bono AV, Celato N, Cova V, Salvadore M, Chinetti S, Novario R. Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis 2002; 5(2): 123−7.

Arakawa A, Soh S, Chakraborty S, Scardino PT, Wheeler TM. Prognostic significance of angiogenesis in clinically localized prostate cancer (staining for Factor VIII-related antigen and CD34 Antigen. Prostate Cancer Prostatic Dis 1997; 1(1): 32−8.

Silberman MA, Partin AW, Veltri RW, Epstein JI. Tumor angi-ogenesis correlates with progression after radical prostatecto-my but not with pathologic stage in gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 1997; 79(4): 772−9.

Tsui KH, Shen BY, Sun GH, Lee SH, Chang PL. Probability based diagnostic biopsy specimens as predictors of tumor grade and stage found. Arch Androl 2004; 50(5): 333−7.

Erbersdobler A, Isbarn H, Dix K, Steiner I, Schlomm T, Mirlacher M, et al. Prognostic value of microvessel density in prostate can-cer: a tissue micro array study. World J Urol 2010; 28(6): 687−92.

Gyftopoulos K, Vourda K, Sakellaropoulos G, Perimenis P, Athanasopoulos A, Papadaki E. The angiogenic switch for vascular endothelial growth factor-A and cyclooxygenase-2 in prostate carcinoma: correlation with microvessel density, androgen receptor content and Gleason grade. Urol Int 2011; 87(4): 464−9.

Matsushima H, Goto T, Hosaka Y, Kitamura T, Kawabe K. Correla-tion between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation. Cancer 1999; 85(8): 1822−7.

Krupski T, Harding MA, Herce ME, Gulding KM, Stoler MH, Theo-dorescu D. The role of vascular endothelial growth factor in the tissue specific in vivo growth of prostate cancer cells. Growth Factors 2001; 18(4): 287−302.

van Niekerk CG, Witjes JA, Barentsz JO, van der Laak JA, Hulsber-gen-van de Kaa CA. Microvascularity in transition zone prostate tumors resembles normal prostatic tissue. Prostate 2013; 73(5): 467−75.

Tretiakova M, Antic T, Binder D, Kocherginsky M. Microvessel density is not increased in prostate cancer: digital imaging of routine sections and tissue microarrays. Hum Pathol 2013; 44(4): 495−502.

Taverna G, Colombo P, Grizzi F, Franceschini B, Ceva-Grimaldi G, Seveso M, et al. Fractal analysis of two-dimensional vascularity in primary prostate cancer and surrounding non-tumoral paren-chyma. Pathol Res Pract 2009; 205(7): 438−44.

Taverna G, Grizzi F, Colombo P, Graziotti PP. Microvessel density estimate: friendorfoe in the light of prostate vascular system complexity. World J Urol 2010; 28(3): 405−6.

Taverna G, Grizzi F, Colombo P, Grazzioti P. Is angiogenesis a hallmark of prostate cancer. Front Oncol 2013; 3(15): 1−3.

Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002; 94(12): 883−93.

Vartanian RK, Weidner N. Endothelial cell proliferation in pros-tatic carcinoma and prostatic hyperplasia: correlation with Gleason's score, microvessel density, and epithelial cell prolif-eration. Lab Invest 1995; 73(6): 844−50.

Lee HJ, Hwang SI, Chung JH, Jeon JJ, Choi JH, Jung HS. Evalua-tion of tumor angiogenesis in a mouse PC-3 prostate cancer model using dynamic contrast-enhanced sonography. J Ultrasound Med 2012; 31(8): 1223−31.

Osimani M, Bellini D, di Cristofano C, Palleschi G, Petrozza V, Car-bone A, et al. Perfusion MDCT of prostate cancer: correlation of perfusion CT parameters and immunohistochemical mark-ers of angiogenesis. AJR Am J Roentgenol 2012; 199(5): 1042−8.

Franiel T, Lüdemann L, Rudolph B, Lutterbeck E, Hamm B, Beyers-dorff D. Differentiation of prostate cancer from normal prostate tissue: role of hotspots in pharmacokinetic MRI and histologic evaluation. AJR Am J Roentgenol 2010; 194(3): 675−81.

Bostwick DG, Foster CS. Predictive factors in prostate cancer: current concepts from the 1999 College of American Patholo-gists Conference on Solid Tumor Prognostic Factors and the 1999 World Health Organization Second International Consultation on Prostate Cancer. Semin Urol Oncol 1999; 17(4): 222−72.